Health Skyhawk’s SKY-0515 Advances Toward Approval for Huntington’s Disease Skyhawk Therapeutics has announced that its investigational drug, SKY-0515, has met the eligibility criteria for provisional registration by Australia’s Therapeutic Goods Administration (TGA). This... Editorial2 March, 2026